ROIVANT SCIENCES LTD
ROIVNASDAQTrading Snapshot
- Day Range
- β
- 52-Week Range
- $19.96 β $42.50
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 722.3M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- $8M
- Last Q Revenue
- $35M
- P/E Ratio
- β
- P/S Ratio
- 3718.5x
- EPS (TTM)
- $-0.39
- Dividend Yield
- β
- Dilution (1yr)
- +3.7%
ROIVANT SCIENCES LTD
ROIVAbout ROIVANT SCIENCES LTD
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates
News unavailable.